filmov
tv
Why Pfizer Is Buying Array BioPharma for $10.6 Billion
Показать описание
Jun.17 -- Pfizer Inc. will buy Array BioPharma Inc. for $10.6 billion to gain its promising new medicines for cancer, which could end or limit the use of punishing chemotherapy for some patients. Bloomberg's Cynthia Koons reports on "Bloomberg Markets."
0:02:33
Why Pfizer Is Buying Array BioPharma for $10.6 Billion
0:00:49
Pfizer buys Array Biopharma for $48/share in cash
0:01:51
Pfizer acquires array biopharma in $10.64B deal
0:03:08
Array BioPharma Soars 59% on Pfizer Mega-Merger
0:04:00
Buy Pfizer or Merck? Activision Blizzard or EA? Plus more in #AskHalftime
0:02:34
Pfizer to Merge Off-Patent Unit With Mylan in All-Stock Deal
0:01:46
Israel in talks to buy Pfizer's Covid-19 vaccine
0:01:09
Pfizer to acquire cancer drug maker Medivation, and other MoneyWatch headlines
0:06:10
Digging into Deals: What's Behind Pfizer's Record-Breaking Acquisition of Allergan
0:01:26
Medivation Said to be Approached by Pfizer About Buyout
0:01:39
Pfizer Partnerships: Bringing the Best Minds Together
0:08:55
Is It Time To Buy Pfizer Stock?
0:04:12
Former Pfizer CEO: Drugs Prices Expensive Because Research Expensive | Power Lunch | CNBC
0:00:36
Pfizer announces major reorganization plan
0:24:08
Pfizer Exec on Biopharmaceuticals Breakthroughs, Pipeline | TYA
0:07:37
Pfizer and Bank of America Stock Analysis!
0:00:35
Jim Cramer Says Pfizer's $14 Billion Acquisition of Medivation is a Strong Purchase
0:02:50
Pfizer to combine off-patent drug business with Mylan
0:01:44
Pfizer Reaches Deal with U.S. for 100 Million Covid-19 Vaccine Doses
0:02:45
Phizer Buys Mylan After Stock Drop
0:01:09
Pfizer expects $15 billion in COVID-19 vaccine sales
0:02:36
Pfizer’s price performance
0:01:47
Pfizer CEO: Made decision to defer drug prices after Trump tweet
0:02:16
Merck, Pfizer jump on earnings: 5 trades
Комментарии